Physician profile
Robin Lesser Androphy
NPI 1770523581
$2,202.04
in general payments reported to CMS, 2019-2025
22 companies · $193 in 2025
The $193 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $206 · 2021: $208 · 2022: $181 · 2023: $343 · 2024: $306 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $834 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $833.85 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $456.67 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $306.96 | 2019-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $244.06 | 2021-2025 | Caplyta |
| Corium, LLC | $185.48 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $164.94 | 2019-2021 | |
| Alkermes, INC. | $148.38 | 2019-2023 | Aristada, Lybalvi |
| Sage Therapeutics, LLC | $116.54 | 2020 | |
| Lundbeck LLC | $91.86 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $74.73 | 2024 | Auvelity |
| Shire North American Group INC | $74.45 | 2019 | |
| Vanda Pharmaceuticals INC. | $67.74 | 2019-2024 | Fanapt |
| Allergan, INC. | $66.04 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $44.10 | 2019 | |
| Bausch Health US, LLC | $33.27 | 2019-2022 | |
| Amgen INC. | $29.54 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $17.88 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.67 | 2019 | |
| Novo Nordisk INC | $15.62 | 2023 | Wegovy |
| Ironshore Pharmaceuticals INC. | $14.80 | 2024 | |
| Idorsia Pharmaceuticals US INC | $14.74 | 2023 | Quviviq |
| Neurocrine Biosciences, INC. | $11.94 | 2019 | |
| Currax Pharmaceuticals LLC | $6.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Androphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.